BRISTOL-MYERS Aktie

>BRISTOL-MYERS Aktienkurs

50.03 EUR -1.6% (TradegateBSX)

Ask: 50.08 EUR / 1200 Stück

Bid: 49.875 EUR / 1250 Stück

Tagesumsatz: 1377 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>BRISTOL-MYERS Performance

1 Woche: -2,8%

1 Monat: -4,6%

3 Monate: +4,3%

6 Monate: +31,7%

1 Jahr: +10,8%

laufendes Jahr: +8,6%

>BRISTOL-MYERS Aktie

Name:

BRISTOL-MYERS SQUIBBDL-10

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1101221083 / 850501

Symbol/ Ticker:

BRM (Frankfurt) / BMY (NYSE)

Kürzel:

FRA:BRM, ETR:BRM, BRM:GR, NYSE:BMY

Index:

S&P500

Webseite:

https://www.bms.com/

Profil:

Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its portfolio addresses critical therapeutic areas inclu..
>Volltext..

Marktkapitalisierung:

103562.19 Mio. EUR

Unternehmenswert:

134575.98 Mio. EUR

Umsatz:

41105.2 Mio. EUR

EBITDA:

16401.48 Mio. EUR

Nettogewinn:

6016.44 Mio. EUR

Gewinn je Aktie:

2.96 EUR

Schulden:

40205.38 Mio. EUR

Liquide Mittel:

8707.37 Mio. EUR

Operativer Cashflow:

12073.81 Mio. EUR

Bargeldquote:

0.46

Umsatzwachstum:

-12.05%

Gewinnwachstum:

Dividende je Aktie:

2.15 EUR

Dividendenrendite:

4.19%

Dividendenschätzung:

4.25%

Div. Historie:

02.04.26 - 0.546777€
02.01.26 - 0.5355€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 1.850.016 USD.

Suchwörter:

BRISTOL-MYERS, BRISTOL MYERS

Letzte Datenerhebung:

11.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 2041.74 Mio. St.

Frei handelbar: 99.81%

Leerverk. Aktien: 1.54%

Rückkaufquote: -

Mitarbeiter: 32500

Umsatz/Mitarb.: 1.26 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 6.62%

Bewertung:

KGV: 17.08

KGV lG: 9.39

KUV: 2.48

KBV: 6.51

PEG-Ratio: -

EV/EBITDA: 8.21

Rentabilität:

Bruttomarge: 65.89%

Gewinnmarge: 14.64%

Operative Marge: 31.36%

Managementeffizenz:

Gesamtkaprendite: 7.72%

Eigenkaprendite: 40.53%

>Anleihen

>Peer Group

Gesundheit, Neurologie/ psychische Behandlung/ Schlaganfälle, Herz-Kreislauf- Behandlung/ Kardiologie, Onkologie/ Krebs- Behandlung

>BRISTOL-MYERS Chart & Kurs - NYSE

>BRISTOL-MYERS News

10.04.26 - 13:42	Bristol Myers, Merck oder Jazz: Die besten Pharma-Aktien für die Quartalssaison (Wallstreet-Online)
	US-Pharmaaktien haben den Markt zuletzt klar geschlagen – doch genau das macht sie anfällig. Bank of America nennt 4 Favoriten für die Quartalssaison und erklärt, warum Zölle kaum eine Rolle spielen....

10.04.26 - 13:36	Bristol Myers, Merck oder Jazz: US-Pharma vor Quartalssaison: Bank of America sieht klare Gewinner (Wallstreet-Online)
	US-Pharmaaktien haben den Markt zuletzt klar geschlagen – doch genau das macht sie anfällig. Bank of America nennt 4 Favoriten für die Quartalssaison und erklärt, warum Zölle kaum eine Rolle spielen....

09.04.26 - 19:45	Does Cobenfy Have the Potential to Become a Top Drug for BMY? (Zacks)
	BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth....

09.04.26 - 16:00	Bristol-Myers Squibb Earnings Preview: What to Expect (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

09.04.26 - 14:48	Oxford BioTherapeutics Partners Bristol Myers Squibb On T-Cell Engager Therapies For Solid Tumors (AFX)
	NEW YORK CITY (dpa-AFX) - Oncology company Oxford BioTherapeutics announced Thursday a multi-year, selective target collaboration with Bristol Myers Squibb Co. (BMY) focused on the discovery and d......

09.04.26 - 01:00	Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts (Zacks)
	In the most recent trading session, Bristol Myers Squibb (BMY) closed at $59.2, indicating a +2.65% shift from the previous trading day....

05.04.26 - 01:01	Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Bristol-Myers Squibb Company im Wert von 1850016 USD (Insiderkauf)
	Elkins, David V. - Vorstand - Tag der Transaktion: 2026-04-01...

02.04.26 - 22:00	Janux Therapeutics Secures $35M Milestone Payment From BMY Deal (Zacks)
	JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform....

02.04.26 - 16:45	Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know (Zacks)
	Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....

01.04.26 - 19:45	Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
	Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

01.04.26 - 14:03

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment (Business Wire)

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux. “This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnerships, and reflects the continued promise of our tumor-activated platforms,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “The nomination of a development candidate highlights our ability to translate platform insights into differentiated therapeutics in col...

01.04.26 - 13:42	Bristol-Myers Squibb Company: Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years (Accesswire)
	New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care PRINCETON, NJ / ACCESS Newswire / April ......

01.04.26 - 01:00	Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
	The latest trading day saw Bristol Myers Squibb (BMY) settling at $60.65, representing a +1.54% change from its previous close....

30.03.26 - 00:06	Bristol Myers drug shows promise for teens with rare heart condition (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.03.26 - 12:42	Bristol-Myers Squibb Company: A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models (Accesswire)
	WASHINGTON, D.C. / ACCESS Newswire / March 27, 2026 / Originally published by the National Council for Mental WellbeingThe collaboration's first initiative is a white paper demonstrating the value ......

26.03.26 - 00:00	Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
	In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day....

25.03.26 - 18:45	Will the Recent Label Expansion of BMY′s Opdivo Boost Its IO Franchise? (Zacks)
	Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation....

23.03.26 - 22:00	Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? (Fool)
	The healthcare company has been a top dividend growth stock for years....

23.03.26 - 18:00	FDA Approves BMY′s Opdivo Label Expansion in Classical Hodgkin Lymphoma (Zacks)
	Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook....

23.03.26 - 13:42	Bristol-Myers Squibb Company: Early Diagnosis and Local Solutions Are Critical To Combat Lung Cancer (Accesswire)
	NORTHAMPTON, MA / ACCESS Newswire / March 23, 2026 / Opinion: Despite advances in prevention and treatment, lung cancer remains the world's deadliest cancer largely because it is often detected too......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer alle Macht hat, muß auch alles fürchten. - Pierre Corneille

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram